Suppr超能文献

原发性甲状腺功能减退症肥胖女性经适当左甲状腺素替代治疗后的静息能量消耗。

Resting Energy Expenditure in Obese Women with Primary Hypothyroidism and Appropriate Levothyroxine Replacement Therapy.

机构信息

Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy.

Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Monza, Italy.

出版信息

J Clin Endocrinol Metab. 2020 Apr 1;105(4). doi: 10.1210/clinem/dgaa097.

Abstract

CONTEXT

Growing evidence suggests that appropriate levothyroxine (LT4) replacement therapy may not correct the full set of metabolic defects afflicting individuals with hypothyroidism.

OBJECTIVE

To assess whether obese subjects with primary hypothyroidism are characterized by alterations of the resting energy expenditure (REE).

DESIGN

Retrospective analysis of a set of data about obese women attending the outpatients service of a single obesity center from January 2013 to July 2019.

PATIENTS

A total of 649 nondiabetic women with body mass index (BMI) > 30 kg/m2 and thyrotropin (TSH) level 0.4-4.0 mU/L were segregated into 2 groups: patients with primary hypothyroidism taking LT4 therapy (n = 85) and patients with normal thyroid function (n = 564).

MAIN OUTCOMES

REE and body composition assessed using indirect calorimetry and bioimpedance.

RESULTS

REE was reduced in women with hypothyroidism in LT4 therapy when compared with controls (28.59 ± 3.26 vs 29.91 ± 3.59 kcal/kg fat-free mass (FFM)/day), including when adjusted for age, BMI, body composition, and level of physical activity (P = 0.008). This metabolic difference was attenuated only when adjustment for homeostatic model assessment of insulin resistance (HOMA-IR) was performed.

CONCLUSIONS

This study demonstrated that obese hypothyroid women in LT4 therapy, with normal serum TSH level compared with euthyroid controls, are characterized by reduced REE, in line with the hypothesis that standard LT4 replacement therapy may not fully correct metabolic alterations related to hypothyroidism. We are not able to exclude that this feature may be influenced by the modulation of insulin sensitivity at the liver site, induced by LT4 oral administration.

摘要

背景

越来越多的证据表明,适当的左甲状腺素(LT4)替代疗法可能无法纠正甲状腺功能减退症患者所患有的全部代谢缺陷。

目的

评估原发性甲状腺功能减退症肥胖患者是否存在静息能量消耗(REE)改变。

设计

对 2013 年 1 月至 2019 年 7 月期间在一家肥胖中心门诊就诊的肥胖女性的一组数据进行回顾性分析。

患者

共有 649 名 BMI>30kg/m2 且 TSH 水平为 0.4-4.0mU/L 的非糖尿病女性患者被分为两组:服用 LT4 治疗的原发性甲状腺功能减退症患者(n=85)和甲状腺功能正常的患者(n=564)。

主要结果

使用间接热量法和生物电阻抗法评估 REE 和身体成分。

结果

与对照组相比,服用 LT4 治疗的甲状腺功能减退症女性的 REE 降低(28.59±3.26 与 29.91±3.59kcal/kg 去脂体重(FFM)/天),包括在调整年龄、BMI、身体成分和身体活动水平后(P=0.008)。仅当进行稳态模型评估的胰岛素抵抗(HOMA-IR)校正时,这种代谢差异才减弱。

结论

本研究表明,与甲状腺功能正常的对照组相比,服用 LT4 治疗的肥胖甲状腺功能减退症女性的 REE 降低,这与标准 LT4 替代疗法可能无法完全纠正与甲状腺功能减退症相关的代谢改变的假设一致。我们不能排除这种特征可能受 LT4 口服给药引起的肝脏胰岛素敏感性的调节影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验